Immunosuppression: practice and trends by Kaufman, Dixon B. et al.
American Journal of Transplantation 2004; 4 (Suppl. 9): 38–53
Blackwell Munksgaard
Blackwell Munksgaard 2004
Immunosuppression: practice and trends
Dixon B. Kaufmana,∗, Ron Shapiro b, Michael R.
Luceyc, Wida S. Cherikhd, Rami T. Bustamie
and David B. Dykef
aNorthwestern University, Feinberg School of Medicine,
Chicago, IL;
bUniversity of Pittsburgh, Pittsburgh, PA;
cUniversity of Wisconsin-Madison, School of Medicine,
Madison, WI;
dUnited Network for Organ Sharing (UNOS), Richmond,
VA;
eUniversity Renal Research and Education Association,
Ann Arbor, MI;
fUniversity of Michigan Health System, Ann Arbor, MI
∗Corresponding author: Dixon B. Kaufman,
d-kaufman2@northwestern.edu
Over the past decade, immunosuppression therapy
has undergone striking changes in the scale and pace
by which new immunosuppressive molecules and an-
tibodies have become incorporated into daily trans-
plant medicine. An organ-by-organ review of data re-
veals several trends. The highest use of induction
therapy (over 70% of patients) was reported for si-
multaneous pancreas kidney (SPK) and pancreas af-
ter kidney (PAK) transplants in 2002; use of induc-
tion therapy was less common in liver transplants
(only 18%). Corticosteroids served as discharge main-
tenance immunosuppression in over 87% of the recipi-
ents of kidney, SPK, PAK and thoracic transplants, and
in over 70% of pancreas transplant alone (PTA) recip-
ients. Corticosteroid use in intestine transplants was
reported in 64% of recipients in 2002. A shift in the cal-
cineurin inhibitor used for maintenance immunosup-
pression from cyclosporine to tacrolimus for the ma-
jority of patients had occurred for kidney, PAK, SPK,
PTA, liver, lung, and heart-lung by 2001. For heart
transplants, cyclosporine remained the calcineurin
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inhibitor of choice; tacrolimus remained the predom-
inant calcineurin inhibitor agent for intestine (since
1994). Use of antibody treatment for rejection during
the first post-transplant year for most organs declined.
Short-term outcomes have improved, based on the ob-
servation that rates of rejection within the first year
post-transplant have diminished.
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Introduction
This article analyzes solid organ transplantation over the
10-year time span of 1993–2002. This period has been
distinguished by marked changes in the clinical practice
of transplantation in general, and in immunosuppressive
strategies in particular. Certain aspects of the evolutionary
changes of immunotherapeutics are captured quite nicely
by the OPTN/SRTR (Organ Procurement & Transplant Net-
work/Scientific Registry of Transplant Recipients) data. Par-
ticularly strong components include the scale and pace by
which the new immunosuppressive molecules and anti-
bodies have become incorporated into the daily activities
of transplant medicine. A careful organ-by-organ review of
the data indicates how much has changed over the 10-year
span beginning in 1993.
Regarding the use of maintenance immunosuppression,
practice patterns indicate a strong role of calcineurin
inhibitor-based immunosuppression. Yet this was occur-
ring during a time when the availability of generic ver-
sions of cyclosporine was expanding and the collective
use of cyclosporines, generally, was rapidly diminishing.
In its place has been a sustained transition to the use
of tacrolimus. Similar trends were also observed with the
antimetabolites azathioprine and mycophenolate mofetil—
the latter being used in the vast majority of transplant
recipients. Recent years have seen the advent of the
novel agent rapamycin, although its use has not mim-
icked the rapid and consistently successful incorpora-
tion of tacrolimus and mycophenolate mofetil. This may
be indicative of uncertainty regarding its role in mainte-
nance immunosuppression in organ transplantation at this
juncture.
One practice trend in the use of maintenance immunother-
apy that is not clearly elucidated by the data is the
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intensity of the immunosuppression. In one respect, it
could be concluded that overall intensity has increased.
Evidence of this viewpoint could be derived from in-
creased use of the potent agents tacrolimus, mycophe-
nolate mofetil, and rapamycin. From another perspective,
there are clues that efforts are ongoing with aims of im-
munosuppression minimization. A hint of that is suggested
by the subtle changes in the reduced application of chronic
corticosteroid therapy. With more detailed data a more pre-
cise assessment could be deduced of the relative dosing
schedules of the individual agents. Unfortunately, one of
the limitations of the data is that it is relatively qualitative in
nature. Specifics regarding the pharmacological exposure
of the recipients to the individual agents are understand-
ably beyond the SRTR aims at this time.
Regarding antibody-based induction therapy, practice pat-
terns indicate that its use and intensity are rising each year.
There are consistent trends indicating a switch to T-cell
depleting agents, especially rabbit antithymocyte globulin.
The lack of quantitative data regarding the actual dosing
and duration of therapy, however, does not allow trends
to be determined in that context. Use of alemtuzumab
(Campath® ILEX Pharmaceuticals, San Antonio, TX) induc-
tion therapy (as an alternative T-cell depleting agent) and rit-
uximab (Rituxan® Genentech, South San Francisco, CA) im-
munotherapy (used in antibody desensitization protocols)
are beginning to be incorporated into practice, but have not
reached a degree of penetration to be meaningful from a
macroscopic viewpoint.
What follows is an examination of general practice trends
in the use of maintenance and induction therapy being ap-
plied to kidney, pancreas, kidney-pancreas, liver, intestine,
heart, heart-lung, and lung transplant recipients. It is the
most complete, detailed, and up-to-date analysis of its kind
available. Importantly, it is only through the collective ef-
forts of the transplant community that this information is
made available to transplant professionals and the multiple
constituents with an interest in the field.
Unless otherwise noted, the statistics in this article come
from reference tables in the 2003 OPTN/SRTR Annual
Report. Two companion articles in this report, ‘Trans-
plant data: sources, collection, and caveats’ and ‘Ana-
lytical approaches for transplant research’, explain the
methods of data collection, organization, and analysis that
serve as the basis for this article (1,2). Additional detail
on the methods of analysis may be found in the ref-
erence tables themselves or in the Technical Notes of
the OPTN/SRTR Annual Report, both available online at
http://www.ustransplant.org.
Kidney Transplantation
Trends in induction therapy in kidney transplantation
The period from 1993 to 2002 has seen a gradual but defini-
















Source: 2003 OPTN/SRTR Annual Report, Table 5.6a.
Figure 1: Trends in kidney transplantation induction immunosup-
pression, 1993–2002.
In 1993, 11% of patients undergoing kidney transplanta-
tion received antibody induction; by 2002 the proportion of
kidney recipients who received antibody induction therapy
was 65%.
In addition to the increased use of antibody preparations
for induction, there has been a marked shift in the type of
antibody preparation (Figure 1). Muromonab-CD3 (OKT3®
Orthobiotech, Bridgewater, NJ), which peaked in use in
1995 (administered to 25% of kidney transplant recipi-
ents) and accounted for virtually all the antibody used for
induction, had fallen to 1% by 2002. Similar trends were ob-
served for equine antithymocyte globulin (ATGAM® Phar-
macia & Upjohn, Kalamazoo, MI). Equine antithymocyte
globulin, which had peaked in use in 1997 (received by
16% of kidney transplant recipients), had fallen to 2%
by 2002. The overwhelming majority of patients receiv-
ing antibody induction in 2002 received agents not avail-
able in 1993. These new agents included rabbit antithy-
mocyte globulin (Thymoglobulin® SangStat Medical Corp.,
Fremont, CA), which accounted for 26% of patients, basil-
iximab (Simulect® Novartis, East Hanover, NJ), which ac-
counted for 27%, and daclizumab (Zenapax® Roche, Nut-
ley, NJ), which accounted for 13% of patients. It is inter-
esting to note that although daclizumab received FDA ap-
proval prior to basiliximab, basiliximab very quickly became
the most commonly used induction agent shortly after its
approval by the FDA. This may be related to the smaller
number of doses (two) associated with its approved use
and the ability to give both doses during the initial hospital-
ization at the time of transplantation.
Induction therapy was used less frequently in recipients
of kidneys from living versus deceased donors, but ad-
ditional SRTR analysis showed that the difference was
small. In 2002, the proportion of living and deceased
donor recipients receiving induction therapy was 62%
and 67%, respectively. With respect to the type of
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induction agent used in recipients of kidneys from de-
ceased donors, rabbit antithymocyte globulin was used
most commonly (29%), followed by basiliximab (27%).
The type of induction agent used most commonly, how-
ever, in recipients of kidneys from living donors was basil-
iximab (27%), followed by rabbit antithymocyte globulin
(21%).
Trends in maintenance immunosuppression therapy
prior to discharge in kidney transplantation
Calcineurin inhibitors. In 1993, 95% of patients undergo-
ing kidney transplantation received cyclosporine; only 2%
received tacrolimus (the latter had not yet been approved
by the FDA) (Figure 2). The trend over the next 10 years
has been a gradual but inexorable decline in the use of cy-
closporine, down to 30% in 2002. Most of the cyclosporine
used has been Neoral® (Novartis, East Hanover, NJ) 22%
and Gengraf® (Abbott, Abbott Park, IL) 7%. Sandimmune®
(Novartis, East Hanover, NJ) accounted for 1% and Eon®
(Eon Labs, Laurelton, NY) for 0.2%. Tacrolimus use has
increased steadily as cyclosporine use has decreased (Fig-
ure 2). In 2002, tacrolimus was used in 63% of kidney trans-
plant recipients. The reasons for this conversion are most
likely related to multicenter trial data that have suggested
lower rates of acute rejection and lower rates of steroid-
resistant rejection associated with tacrolimus (3,4). Cos-
metic issues, i.e. the absence of hirsutism with tacrolimus,
have also played a role.
Antimetabolites and rapamycin. In 1993, azathioprine, the
only routinely available antimetabolite, was used in 86% of
kidney transplant recipients; by 2002 this had decreased
to 2% (Figure 2). Mycophenolate mofetil, which was ap-
proved by the FDA in 1995, has seen its use increase to
79% of patients undergoing kidney transplantation. This
high percentage rate has remained relatively constant over
the last several years. In all, 81% of kidney recipients re-
ceived some sort of antimetabolite in 2002. Rapamycin
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Figure 2: Trends in kidney transplant maintenance immunosup-
pression prior to discharge, 1993–2002.
down slightly from 17% in 2001. The most popular com-
bination regimen in recent years has included tacrolimus
and mycophenolate mofetil, which has been utilized in the
majority of patients undergoing kidney (or pancreas) trans-
plantation. This combination has been shown to be effec-
tive in several single and multicenter prospective random-
ized trials (4–6).
Corticosteroids. In 1993, 99% of patients received corti-
costeroids, either in the form of intravenous methylpred-
nisone or prednisone. In 2002, 91% of patients received
corticosteroids, suggesting that there is a growing percent-
age of patients who are receiving either steroid avoidance
or near avoidance protocols after kidney transplantation
(7–9).
Trends in maintenance immunosuppression therapy
for the first year in kidney transplantation
Calcineurin inhibitors. The data in this section mirror the
data described in the previous section. Cyclosporine was
used in 96% of kidney transplant recipients in 1992. This
had decreased to 39% by 2001. In 2001, Neoral® ac-
counted for the vast majority of cyclosporine use (31%),
Gengraf® accounted for 9%, Sandimmune® 3%, and Eon®
0.3%. Tacrolimus, which had not yet been approved in
1992, accounted for 3% of kidney transplant patients; by
2001 this figure had increased to 64%, probably for the
reasons discussed above.
Antimetabolites and rapamycin. The use of antimetabolites
remained high in 2001 at 83% in kidney transplant recipi-
ents, however this was down somewhat from 1999, when
it was 89%. Azathioprine usage decreased from 87% in
1992 to 6% in 2001, and mycophenolate mofetil increased
from 1% in 1992 to 80% in 2001. Rapamycin use increased
from 0% in 1992 to 21% in 2001; virtually all this increase
has occurred since its FDA approval in 1998.
Corticosteroids. Corticosteroids again remain in use in vir-
tually all patients undergoing kidney transplantation; this
percentage has fallen very slightly from 99.5% in 1992 to
96% in 2001, suggesting that there is a small but growing
percentage of patients who are no longer receiving corti-
costeroids.
Trends in antirejection treatment in kidney
transplantation
The first important observation to be made about antire-
jection treatment is that the need for it has decreased dra-
matically. In 1992, the percentage of kidney transplant re-
cipients undergoing antirejection treatment was 38%, by
2001 it was 17% (Figure 3). In terms of therapies for re-
jection, the overwhelming majority of cases were treated
with corticosteroids, and this percentage has changed little
over the years, remaining at 81% in 1992 and in 2001. Anti-
body therapy use has decreased over the years, from 53%
in 1992 to 37% in 2001. The specific antibodies used to

























Source: 2003 OPTN/SRTR Annual Report, Table 5.6d.

























Source: 2003 OPTN/SRTR Annual Report, Table 5.6d.
Figure 4: Trends in antibody therapy for rejection episodes fol-
lowing kidney transplantation.
treat rejection, however, have changed dramatically (Fig-
ure 4). Antilymphocyte globulin (ALG), which peaked at
21% in 1993, has disappeared from practice. Muromonab-
CD3, which peaked at 44% in 1993, is now down to 11%.
The use of rabbit antithymocyte globulin, which was 0%
in 1993, is now up to 18%. Interestingly, in 2001, the
interleukin-2 (IL-2) receptor antagonists daclizumab and
basiliximab were used in 3% and 5% of patients, respec-
tively, as antirejection therapy, although there are little data
supporting their use.
Pancreas Transplantation
Trends in induction therapy in pancreas
transplantation
The use of induction therapy has been shown to signifi-
cantly improve pancreas graft survival rates in several sub-
groups. According to data from the International Pancreas
Transplant Registry, the use of induction therapy in simul-
taneous pancreas-kidney (SPK) transplant recipients with
systemic venous-enteric exocrine drainage significantly im-
proves pancreas graft survival rates (10,11). Interestingly,
pancreas graft survival is not improved with induction ther-
apy in the subgroups with portal venous-enteric or bladder
drainage. Furthermore, SPK transplant recipients who re-
ceive induction therapy benefit from a reduced incidence
and severity of biopsy-confirmed, treated, acute kidney
rejection episodes. In recipients given anti-T-cell deplet-
ing induction agents, however, there was also a statisti-
cally significantly higher rate of CMV viremia/syndrome,
especially in the subgroup of recipients who received or-
gans from CMV serologically positive donors (12). For the
numerically smaller groups of solitary pancreas recipients
(pancreas after kidney (PAK) and pancreas transplant alone
(PTA)), the addition of induction therapy is associated with
a clinically significant improvement in pancreas graft sur-
vival rates. In the PAK category, the 3-year actuarial pan-
creas graft survival with induction therapy is 74% vs. 64%
without. In the PTA category, the 1-year functional sur-
vival rate for recipients with induction therapy was 86% vs.
74% without.
The use of antibody induction in pancreas transplant re-
cipients has been relatively more common than in kidney
transplantation. In SPK recipients, induction was used in
74% of patients in 2002. As in kidney transplantation, the
specific agents have changed dramatically (Figure 5), so
that while muromonab-CD3 was used in 56% of patients
in 1995, use had decreased to 0.9% by 2002. Similarly,
while equine antithymocyte globulin was used in 30% of
cases undergoing SPK in 1997, use had decreased to 3%
by 2002. Between 1993 and 2002, the use of rabbit an-
tithymocyte globulin increased from 0% to 37%; the use
of daclizumab increased from 0% to 16%; and the use of
basiliximab increased from 0% to 25%. In PAK and PTA pa-
tients, the same trends are observed. In PAK, no antibody
induction was used in 1993, but in only 28% of cases in
2002 was antibody induction not used. Most of the an-
tibody induction in 2002 was with rabbit antithymocyte



















Source: 2003 OPTN/SRTR Annual Report, Table 8.6a.
Figure 5: Trends in simultaneous kidney-pancreas transplantation
induction immunosuppression, 1993–2002.
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Similarly, in PTA patients, antibody induction was not used
in 33% of patients in 2002; 58% received rabbit antithymo-
cyte globulin, 34% received daclizumab, and 5% received
basiliximab.
Trends in maintenance immunosuppression therapy
prior to discharge in pancreas transplantation
Calcineurin inhibitors. The decrease in the use of cy-
closporine between 1993 and 2002 has been even more
pronounced in kidney-pancreas transplants (Figure 6). In
1993, 98% of patients received cyclosporine; this was
down to 9% in 2002, with 7% receiving Neoral®, 2%
receiving Gengraf®, 0.7% receiving Sandimmune®, and
0.2% receiving Eon®. Tacrolimus usage increased to 87%
of SPK recipients in 2002, up from 0% in 1993. Similar
findings have been noted in both PAK and PTA patients;
tacrolimus use increased from 0% to 86% between 1993
and 2002 in PAK patients and from 10% to 95% in PTA
patients.
Antimetabolites and rapamycin. As in kidney-pancreas
transplants, antimetabolites continued to be used in the
vast majority of patients, although this percentage de-
creased from 95% in 1993 to 80% in 2002 (Figure 6). Aza-
thioprine usage fell from 95% to 0.9%, while mycopheno-
late mofetil has increased from 0% to 79%; this is down
somewhat from 1999, where 88% of SPK patients re-
ceived mycophenolate mofetil, and probably reflects the
increased use of rapamycin. Rapamycin use in SPK pa-
tients increased from 0% in 1993 to as high as 20% in
2001; in 2002 it was down to 18%. In PAK patients, the
use of antimetabolites decreased from 100% to 74%. Aza-
thioprine usage decreased from 100% to 0.3%. Mycophe-
nolate mofetil use increased from 0% to 74%, but this
represents a decrease from a peak of 92% in 1997. In PAK
patients, the use of rapamycin increased from 0% to a
peak of 21% in 2001, down to 19% in 2002. In PTA pa-
tients, antimetabolite usage decreased from 87% in 1993
































Azathioprine Mycophenolate mofetil Sirolimus/rapamycin
Figure 6: Trends in SPK transplant maintenance immunosuppres-
sion prior to discharge, 1993–2002.
peared, decreasing from 87% to 1%, and mycophenolate
mofetil usage increased from 0% to 64%, the latter rep-
resenting a decrease from 89% in 1997. In PTA patients,
rapamycin usage increased steadily from 0% in 1993 to
16% in 2002.
Corticosteroids. Corticosteroids were used in 99% of pa-
tients undergoing SPK in 1993; this has decreased over the
last couple of years to 87% in 2002, reflecting an increased
use of steroid-free protocols (13). In PAK patients, the data
from the early 1990s seem somewhat incomplete, but the
percentages from 1997 and 1998, with 95% and 99% re-
ceiving steroids, decreased slightly to 89% by 2002. For
PTA patients, the same trends were observed.
Trends in maintenance immunosuppression therapy
for the first year in pancreas transplantation
Calcineurin inhibitors. The change in the use of calcineurin
inhibitors has again been more marked in kidney-pancreas
transplants. Cyclosporine use decreased from 99.8% to
16% between 1992 and 2001; most of this again was
with Neoral® 12%, Gengraf® 3%, Sandimmune® 2%, and
Eon® 0.4%. In SPK recipients, tacrolimus use rose from
0.5% in 1992 to 89% in 2001. The findings in PAK and
PTA patients were even more dramatic. In PAK patients,
cyclosporine use decreased from 100% in 1992 to 15% in
2001; tacrolimus use increased from 0% to 93%. In PTA
patients, cyclosporine use decreased from 89% to 8% be-
tween 1992 and 2001, and tacrolimus use increased from
11% in 1992 to 99% in 2001.
Antimetabolites and rapamycin. Antimetabolite use de-
creased from 99% in 1992 to 79% in 2001 in kidney-
pancreas transplants. There was a shift from azathioprine,
which decreased from 99% to 2% during this time pe-
riod, to mycophenolate mofetil, which went up from 0%
to 78%. The latter number is a decrease from 1998, where
92% of SPK patients received mycophenolate mofetil; it
probably reflects the increasing use of rapamycin. In PAK
and PTA patients, the same trends are present. There has
been a steady increase in the use of rapamycin in SPK
patients, increasing from 0% to 27% between 1992 and
2001. This has been mirrored in PAK patients, rapamycin
use has gone up from 0% to 29%. In PTA patients, ra-
pamycin use has increased from 0% to 15% (the latter,
however, presents a decrease from 2000, where 25% of
PTA patients received rapamycin).
Corticosteroids. Corticosteroid use in SPK patients de-
creased slightly from 100% in 1992 to 92% in 2001, reflect-
ing an increased use of steroid-weaning protocols (14,15).
Steroid use, however, has remained relatively stable in PAK
patients and is almost as high in PTA patients.
Trends in antirejection treatment in pancreas
transplantation
As in kidney transplantation, there has been a marked re-
duction in the need for antirejection therapy. From 1992 to


























Source: 2003 OPTN/SRTR Annual Report, Table 8.6d.
Figure 7: Trends in incidence of rejection at 1 year in simultaneous




















Source: 2003 OPTN/SRTR Annual Report, Table 8.6d.
70
Figure 8: Trends in antibody therapy for rejection episodes fol-
lowing simultaneous kidney-pancreas transplantation.
2001, the incidence of rejection in SPK patients declined
from 66% to 19%, in PAK patients from 45% to 14%,
and in PTA patients from 54% to 13% (Figure 7). Anti-
body use decreased from 73% in 1992 to 29% in 2001
in SPK patients, and again the type of agents changed
from muromonab-CD3 and equine antilymphoblast glob-
ulin (61% and 25%, respectively, in 1992) to rabbit an-
tithymocyte globulin and muromonab-CD3 (accounting
for 17% and 12% of patients, respectively, in 2001)
(Figure 8). Corticosteroid usage has remained stable at just
over 85%. In PAK and PTA patients, antibody therapies
were used in a somewhat higher percentage of patients
by 2001 (63% in PAK patients, 62% in PTA patients). The
nature of these agents has also changed, as in the case
of SPK.
Liver Transplantation
Trends in induction therapy in liver transplantation
According to OPTN/SRTR data, between 1993 and 2001,
the use of induction agents varied from 10% to 15%
















Source:  2003 OPTN/SRTR Annual Report, Table 9.6a.
Figure 9: Trends in liver transplantation induction immunosup-
pression, 1993–2002.
18%. During the last 10 years, the induction agents of
choice have undergone gradual change. Earlier in the era,
muromonab-CD3 was the predominant agent used, reach-
ing a zenith in 1995 when 10% of recipients received it.
Since then, the use of muromonab-CD3 has declined to al-
most nil, whereas the use of monoclonal anti-IL2 receptor
agents has increased, so that by 2002, 13% of recipients
received either daclizumab or basiliximab (Figure 9). There
also has been a modest resurgence in the use of rabbit
antithymocyte globulin.
The reasons behind the gradual increased use of induc-
tion agents over the past 5 years are not clear. There are
few studies to support or refute the use of antilympho-
cyte induction therapy in primary or repeated liver trans-
plantation. One possible explanation is the introduction in
2002 of MELD-based allocation, in which liver transplan-
tation candidates with renal failure receive priority; if such
patients are being transplanted more quickly, it may reflect
increased use of such agents as calcineurin inhibitor spar-
ing agents in this population.
Trends in maintenance immunosuppression therapy
prior to discharge in liver transplantation
Serial data from 1993 through 2002 show some consistent
patterns of immunosuppressant use prior to discharge.
Throughout the period, liver allograft recipients were man-
aged on multiple drug regimens based on corticosteroids
and calcineurin inhibitors. Consistently, at least 50% of
recipients received an antimetabolite. During the period for
which data have been collected, there have been minor and
inconsistent variances in the prevalence of corticosteroid
use, so that 90% of recipients were discharged on corti-
costeroids in 2002, compared with 95% in 1993 or 88% in
1995.
Calcineurin inhibitors. In contrast, there have been striking
shifts in drug selection among the calcineurin inhibitors
and antimetabolites (Figure 10). For example, whereas cy-
closporine (in any of its formulations) was administered to
83% of recipients prior to discharge in 1993, its rate of
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Figure 10: Trends in liver transplant maintenance immunosup-
pression prior to discharge, 1993–2002.
use has declined every year since then to reach its cur-
rent nadir of 10% in 2002. Whether the newly introduced
practice of monitoring the blood level 2 h (C2 monitoring)
after ingestion rather than fasting trough levels will reverse
this trend remains to be seen. The decline in use of cy-
closporine has been mirrored by the increase in use of
tacrolimus. Its use in immunosuppressant management
prior to discharge increased every year from 1993 (18%)
to 2002 (87%).
Antimetabolites and rapamycin. Similarly, azathioprine was
the antimetabolite of choice in 1993, being administered
to 58% of recipients. This rate of use declined annually
until 2001, when it reached a nadir of 3%. In 2002, aza-
thioprine use showed a modest increase to 4%. At the
same time azathioprine declined, mycophenolate mofetil
gained in use, from 0.6% in 1993 to 48% in 2002 (Fig-
ure 10). These data suggest, but do not prove, that my-
cophenolate mofetil has replaced azathioprine in circum-
stances where the managing physicians believe that an
antimetabolite is required. Finally, there has been a small
increase in the use of rapamycin in the early postopera-
tive period. It was administered to 9% and 10% of recipi-
ents in 2000 and 2001, respectively. Curiously, this preva-
lence of use declined to 7% in 2002, perhaps on account
of reported difficulties with early postoperative manage-
ment, such as wound healing and integrity of the vascular
anastomoses.
Trends in maintenance immunosuppression therapy
for the first year in liver transplantation
Perhaps the most surprising aspect of the OPTN/SRTR data
on maintenance immunosuppression between discharge
and the end of the first year is the unchanging results for
use of corticosteroids. Thus, 93% of recipients in 1993
and 90% of recipients in 2001 received corticosteroids for
their first postoperative year. This is curious because of the
widespread discussion of steroid reduction and withdrawal
after liver transplantation (16–18). There are a number of
possible explanations for this discrepancy. First, practice
may have changed since 2001; if so, more contemporary
data will show less use of corticosteroids. Second, there
may be a gap between actual practice and what is advo-
cated in publications, with practice not changing as much
as anticipated. Third, the presented data do not consider
the doses of corticosteroids in use, which may have been
reduced over the past 10 years, albeit without withdrawal.
Finally, the interval from discharge to the end of year 1 may
be too brief, and data on maintenance up to year 5 might
be more indicative of steroid withdrawal. In any case, the
present data do not confirm a major shift away from the use
of corticosteroids for maintenance immunosuppression in
the first year after liver transplantation.
The data on calcineurin inhibitors and antimetabolites in
the first year mirror the data reported prior to discharge,
namely: (i) the widespread use of tacrolimus where pre-
viously cyclosporine was the favored calcineurin inhibitor
and (ii) the reduction in use of azathioprine and concomitant
adoption of mycophenolate mofetil as the antimetabolite
of choice. A small but significant percentage of patients
also received rapamycin, the use of which grew from 0%
in 1997 to 17% in 2001. These data do not address specif-
ically the combinations in use. Nevertheless, judging by
these data, even in 2001, more that 80% of liver trans-
plant recipients were receiving at least two immunosup-
pressives (both corticosteroids and tacrolimus) and approx-
imately half were receiving three.
Trends in antirejection treatment in liver
transplantation
The proportion of liver transplant recipients treated for re-
jection has diminished over the 10-year time span, 1992
(47%) through 2001 (28%). During the most recent time
period (1996 through 2001), however, the rate remained
nearly constant (32% and 28%, respectively) (Figure 11).
With respect to treatment therapies for rejection, the ma-
jority of cases were treated with corticosteroids. The per-
























Source: 2003 OPTN/SRTR Annual Report, Table 9.6d.
Figure 11: Trends in incidence of rejection at 1 year in liver trans-
plant recipients, 1992–2001.






















Source: 2003 OPTN/SRTR Annual Report, Table 9.6d.
Figure 12: Trends in antibody therapy for rejection episodes fol-
lowing liver transplantation.
to 89% in 2001. Antibody therapy decreased slightly over
the years, from 33% in 1992 to 17% in 2001. The nature
of the antibodies used to treat rejection changed dramati-
cally (Figure 12). Muromonab-CD3, which peaked at 34%
in 1993, went down to 7% in 2001. Rabbit antithymocyte
globulin, for which usage was 0% in 1993, was used in
5% of cases in 2001. Interestingly, the IL-2 receptor antag-
onists daclizumab and basiliximab were used in 2% and 4%
of patients, respectively, as antirejection therapy in 2001,
although there are little data supporting their use.
Intestinal Transplantation
Trends in induction therapy in intestinal
transplantation
The numbers of intestinal transplants remain small, 107
in 2002. The data presented do not distinguish between
combined liver-small bowel transplantation and isolated
small bowel transplantation. In the past 5 years, induc-
tion chemotherapy has become more common. The preva-
lence has risen from 41% in 1998 to 57% in 2002. Rab-
bit antithymocyte globulin, basiliximab, and daclizumab
were all used, without one agent establishing clinical
predominance.
Trends in maintenance immunosuppression therapy
prior to discharge in intestinal transplantation
Calcineurin inhibitors. Exclusive and almost universal use
of tacrolimus (96% in 2002) has been the pattern prior to
discharge throughout the period under review. Conversely,
cyclosporine was used in no patients. Up to year 2000,
there was a similar, almost universal use of corticosteroids.
In the most recent 2 years, however, corticosteroid use
prior to discharge has declined to 80% and 64%, respec-
tively. These data are difficult to explain, especially since
a similar decline was not observed in corticosteroid use in
the first year after discharge (see below).
Antimetabolites and rapamycin. Rapamycin was used prior
to discharge in 19% of intestinal transplant recipients in
2002. This frequency had declined from a peak of 39% in
2000. Given the small numbers, it is difficult to infer the rea-
sons for such changes in practice. The use of antimetabo-
lite agents has been similarly inconsistent, and, most re-
cently, no recipients were recorded as receiving azathio-
prine and only 11% received mycophenolate mofetil.
Trends in maintenance immunosuppression therapy
for the first year in intestinal transplantation
The practice patterns for maintenance immunosuppres-
sion from discharge through the first year mirror those
described above for transplant admission. Once again,
tacrolimus was used in all recipients to the absolute exclu-
sion of cyclosporine. This pattern has remained unchanged
since 1996. Corticosteroids were also almost universal dur-
ing this period, a pattern that has remained constant with
minor variations since 1993.
The use of other agents is much less consistent over time.
No clear trend regarding antimetabolites was discernable,
with wide shifts from year to year. While recognizing the
limited data, it appears that mycophenolate mofetil, which
peaked at 57% in 1996, had fallen out of favor and was
administered to only 3% of cases in 2001. Rapamycin was
recorded in 1999, 2000, and 2001 only. The frequency of
its use has fluctuated widely.
Trends in antirejection treatment in intestinal
transplantation
The proportion of intestine transplant recipients treated for
rejection over the first post-transplant year has diminished
over the 10-year time span, from 1992 (77%) through 2001
(36%). The data do not indicate the proportion of recipi-
ents with multiple rejection episodes. With respect to treat-
ment therapies for rejection, virtually all recipients received
corticosteroids as part of their antirejection therapy. Anti-
body therapy remained relatively constant: 48% in 1993
and 35% in 2001. The nature of the antibodies used to
treat rejection has not changed appreciably. In 1993, all
antibody therapy was muromonab-CD3. It is still the most
commonly used antibody for treating rejection. Rabbit an-
tithymocyte globulin was used in 8% of cases in 2001.
Heart Transplantation
Trends in induction therapy in heart transplantation
Trends for the use of induction therapy in heart transplan-
tation have been similar to those seen in kidney transplan-
tation, however there appears to be a lag time of roughly
2 years. This probably represents the general reluctance of
thoracic organ transplant physicians to try newer therapies
until safety and efficacy have been established in other
organ groups. In general, over the last decade, there has
been an increase in the percentage of patients receiving
induction therapy, from 12% in 1993 to 45% in 2002. This
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Source: 2003 OPTN/SRTR Annual Report, Table 11.6a.
Figure 13: Trends in heart transplantation induction immunosup-
pression, 1993–2002.
may be explained, in part, by the fact that a higher risk pop-
ulation (i.e. patients presenting with more diabetes, renal
dysfunction, and older age) is now being transplanted than
a decade ago. There have been several obvious trends for
specific agents (Figure 13). The most frequently used in-
duction agents have been muromonab-CD3 and equine an-
tithymocyte globulin; however, their use has rapidly fallen
off in the last several years to 5% and 7%, respectively.
In contrast, the use of rabbit antithymocyte globulin has
increased from 0% 4 years ago to 16% in 2002. Likewise,
the use of anti-IL-2 receptor antibodies (daclizumab and
basiliximab) has increased from 0% 5 years ago to 18% in
2002. The use of either rabbit antithymocyte globulin or an
anti-IL-2 receptor antibody now appears to be the dominant
strategy for induction in heart transplantation.
Trends in maintenance immunosuppression therapy
prior to discharge in heart transplantation
From 1993 to 2002, there have been no major changes in
the general scheme of immunosuppression therapy prior
to discharge for heart transplant recipients. The basic ther-
apeutic strategy for the majority of patients still includes a
calcineurin inhibitor, an antimetabolite, and corticosteroids.
There have been, however, some fairly dramatic changes
in agents within each class.
Calcineurin inhibitors. Calcineurin inhibitor use at the time
of discharge remains essentially 100% (Figure 14). Cy-
closporine remains the most frequently used calcineurin
inhibitor, although its use has fallen from 98% in 1993 to
61% in 2002. Of those who received cyclosporine, approx-
imately 46% received Neoral® and 13% received Gengraf®
(a small percentage, 3%, received Sandimmune®). The use
of tacrolimus has increased proportionally to the decrease
in cyclosporine use. Tacrolimus is now used in 39% of heart
transplant recipients at the time of discharge.
Antimetabolites and rapamycin. The use of antimetabolites
(azathioprine and mycophenolate mofetil) at the time of dis-
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Figure 14: Trends in heart transplant maintenance immunosup-
pression prior to discharge, 1993–2002.
ranging from 96% in 1993 to 84% in 2002 (Figure 14).
Within this class of immunosuppressants, mycophenolate
mofetil has assumed the dominant role over the past few
years. In 2002, mycophenolate mofetil was used in 75% of
heart transplant recipients at the time of discharge, while
azathioprine use had fallen to 12%. A slight fall-off in an-
timetabolite use over the past few years is probably ex-
plained by the increasing use of rapamycin, now used in
10% of heart transplant recipients at the time of discharge.
Other agents, such as cyclophosphamide, are rarely used
in heart transplantation.
Corticosteroids. Use of corticosteroids has fluctuated little
in the past decade (a low of 94%, a high of 97%). In 2002,
corticosteroids were used in 97% of heart transplant recip-
ients at the time of discharge.
Trends in maintenance immunosuppression therapy
for the first year in heart transplantation
In 2001, the most common maintenance therapy combina-
tion for heart transplant recipients within the first year after
transplantation consisted of corticosteroids, cyclosporine
or tacrolimus, and mycophenolate mofetil.
Calcineurin inhibitors. Therapy with cyclosporine or
tacrolimus remains the cornerstone of maintenance im-
munosuppression in heart transplant recipients. Over the
past 10 years, there has been a trend towards less use
of cyclosporine and more use of tacrolimus. Cyclosporine
use has decreased from 99% in 1992 to 65% in 2001, with
Neoral® being the most frequent formulation. The use of
tacrolimus has greatly increased from 1% to 43% during
the same time interval.
Antimetabolites and rapamycin. Although antimetabolites
are still frequently used within the first year after heart
transplantation, there has been a shift in practice over the
last 10 years. The use of azathioprine dominated up until
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1996 (97% in 1992, down to 15% in 2001). The use of
mycophenolate mofetil now appears to be standard prac-
tice (81% in 2001) in heart transplantation. Overall, there
appears to be a slight decline in the use of the standard
antimetabolites as a class. In 1992, approximately 97% of
heart transplant recipients received either azathioprine or
mycophenolate mofetil. In 2001, the use of either azathio-
prine or mycophenolate mofetil fell to 95%. Concurrent
with this trend, there was an increase in use of other novel
immunosuppressant agents. In 2001, approximately 8% of
heart transplant recipients received rapamycin within the
first year after transplantation.
Corticosteroids. The vast majority of heart transplant re-
cipients are treated with corticosteroids as part of main-
tenance therapy during the first year after transplanta-
tion. Over the last 10 years, there has been no clear
trend in the use of corticosteroids. In 2001, 91% of
heart transplant recipients received either prednisone or
methylprednisolone.
Trends in antirejection treatment in heart
transplantation
In the last decade, it appears that the rates for treatment
of rejection within the first year after heart transplantation
have not changed (39% in 1992 and 38% in 2001) (Fig-
ure 15). For patients who require therapy for rejection, the
use of corticosteroids has remained between 88% and
92%. During the last 10 years, the use of therapy with
antibodies gradually decreased from 23% to 16%. When
antibody therapy was used, muromonab-CD3 remained
the most frequently used preparation, although its use has
declined. In 1993, muromonab-CD3 was used in 24% of
cases of rejection, whereas in 2001 it was used in only
6%. The use of equine antithymocyte globulin varied from
1% in 1992 to 7% in 1995, although the use of this agent
may be declining (4% in 2001). The use of rabbit antithy-
mocyte globulin has been steadily increasing over the past























Source: 2003 OPTN/SRTR Annual Report, Table 11.6d.



















Source: 2003 OPTN/SRTR Annual Report, Table 11.6d.
Figure 16: Trends in antibody therapy for rejection episodes fol-
lowing heart transplantation.
antibodies for the treatment of rejection had increased to
approximately 3% in 2001.
In summary, the treatment of rejection within the first
year after heart transplantation remains based on corti-
costeroids, with a gradual decline in the use of antibody
therapy noted over the past several years. When antibody
therapy is used, there appears to be no consensus as to
the specific preparation (Figure 16).
Lung Transplantation
Trends in induction therapy in lung transplantation
The trends for the use of induction therapy in lung trans-
plantation have been similar to those seen in heart trans-
plantation, with a general decrease seen in the use of
muromonab-CD3 and equine antithymocyte globulin, and
a concurrent increase in the use of rabbit antithymo-
cyte globulin and anti-IL-2 receptor antibodies (daclizumab
and basiliximab) (Figure 17). In general, over the last
10 years, there has been a gradual increase in the per-
centage of patients receiving induction therapy, from 3%
in 1993 to 41% in 2002. There have been several ob-
vious trends for specific agents. The most frequently
used induction agent over the last 10 years was equine
antithymocyte globulin, peaking in 1995 at 23%; how-
ever, in 2002, it was only reported in 7% of lung trans-
plant recipients. The use of muromonab-CD3 peaked in
1994 at 6% but has now fallen to less than 0.6% in lung
transplantation. In contrast, the use of rabbit antithymo-
cyte globulin has increased from 0% 4 years ago to 9%
in 2002. Likewise, the use of anti-IL-2 receptor antibod-
ies (daclizumab and basiliximab) has increased from 0%
6 years ago to 25% in 2002. The use of either rabbit an-
tithymocyte globulin or an anti-IL-2 receptor antibody now
appears to be the dominant strategy for induction in lung
transplantation.
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Source: 2003 OPTN/SRTR Annual Report, Table 12.6a.
Figure 17: Trends in lung transplantation induction immunosup-
pression, 1993–2002.
Trends in maintenance immunosuppression therapy
prior to discharge in lung transplantation
As in heart transplantation, from 1993 to 2002, there
have been no major changes in the general scheme of
immunosuppression therapy prior to discharge for lung
transplant recipients. Within the certain specific classes of
immunosuppressants, however, there have been dramatic
shifts in practice.
Calcineurin inhibitors. Calcineurin inhibitor use at the
time of discharge remains essentially 100%. Cyclosporine
is no longer the most frequently used calcineurin in-
hibitor. Cyclosporine fell from 91% in 1993 to 43% in
2002. Of those who received cyclosporine, most received
Neoral®. A small proportion received either Gengraf®
or Sandimmune®. In contrast, the use of tacrolimus
increased substantially. Tacrolimus is now used in 57%
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Figure 18: Trends in lung transplant maintenance immunosup-
pression prior to discharge, 1993–2002.
Antimetabolites and rapamycin. The use of antimetabo-
lites (azathioprine and mycophenolate mofetil) at the time
of discharge has remained fairly constant over the past
10 years, ranging from 98% in 1993 to 90% in 2002. Al-
though the use of azathioprine has declined, and the use
of mycophenolate mofetil has proportionally risen, this has
not occurred to the same extent as is seen in heart trans-
plantation. In 2002, azathioprine was used in 46% of lung
transplant recipients at the time of discharge and mycophe-
nolate mofetil was used in 45% (Figure 18). The use of
rapamycin has not, as of yet, played much of a role in lung
transplantation. Peak use in 2001 was only 4%. In 2002, ra-
pamycin was only used in 2% of lung transplant recipients
at the time of discharge. Other agents, such as cyclophos-
phamide, were rarely used in lung transplantation.
Corticosteroids. Use of corticosteroids fluctuated little in
the past decade (a low of 97% and a high of 99%). In
2002 corticosteroids were used in 99% of lung transplant
recipients at the time of discharge.
Trends in maintenance immunosuppression therapy
for the first year in lung transplantation
In 2001, the most common maintenance therapy combi-
nation for lung transplant recipients within the first year af-
ter transplantation consisted of corticosteroids, tacrolimus,
and either azathioprine or mycophenolate mofetil.
Calcineurin inhibitors. As in heart transplantation, cy-
closporine or tacrolimus remain the cornerstone of main-
tenance immunosuppression in lung transplant recipients.
In the past decade, there was a trend toward less use
of cyclosporine and more use of tacrolimus, to the point
where tacrolimus now appears to be the agent of choice.
Cyclosporine use has decreased from 93% in 1992 to 46%
in 2001, with Neoral® being the most frequent formulation.
The use of tacrolimus has increased from 7% to 69% dur-
ing the same time interval.
Antimetabolites and rapamycin. Although antimetabolites
are still frequently used within the first year after lung
transplantation, there was a shift in practice over the last
decade. The use of azathioprine declined from 97% in 1992
to 49% in 2001. The use of mycophenolate mofetil con-
currently increased from 0% to 52% over the same time
period. Overall, there appeared to be a slight decline in the
use of standard antimetabolites as a class. In 1992, approx-
imately 97% of lung transplant recipients received azathio-
prine. In 2001, the use of either azathioprine or mycophe-
nolate mofetil fell to 91%. Concurrent with this trend, there
was an increase in use of other novel immunosuppressant
agents. In 2001, approximately 11% of lung transplant re-
cipients received rapamycin within the first year after trans-
plantation. Recent trends, however, show a decrease in
use, perhaps related to the observation that airway anas-
tomotic dehiscence is associated with use of rapamycin
immediately after lung transplantation (19).
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Corticosteroids. The vast majority of lung transplant recip-
ients are treated with corticosteroids as part of mainte-
nance therapy during the first year after transplantation.
Within the last decade, there has been no clear trend in
the use of corticosteroids. In 2001, nearly 100% of lung
transplant recipients received either prednisone or methyl-
prednisolone.
Trends in antirejection treatment in lung
transplantation
In the last decade, it appears that the rates for treatment
of rejection within the first year after lung transplantation
did not change substantially (48% in 1992 and 45% in
2001) (Figure 19). For patients who required therapy for
rejection, the use of corticosteroids has remained between
88% and 97%.
During the last 10 years, the use of therapy with antibod-
ies ranged from 9% to 18%, with no clear trend. When
antibody therapy was used, equine antithymocyte globu-
lin was the most frequently used preparation, although its
use declined from 10% in 1994 to 4% in 2001. The use
of muromonab-CD3 declined from 10% in 1993 to 2% in
2001. The use of rabbit antithymocyte globulin has steadily
increased over the past several years to 6% in 2001. The
use of anti-IL-2 receptor antibodies for the treatment of
rejection was approximately 1% in 2001.
In summary, the treatment of rejection within the first
year after lung transplantation remains based on corticos-
teroids. The use of antibody therapy gradually increased
between 1995 (10%) and 2000 (18%), however its usage
decreased in 2001 (12%). When antibody therapy is used,

























Source: 2003 OPTN/SRTR Annual Report, Table 12.6d.




















Source: 2003 OPTN/SRTR Annual Report, Table 12.6d.
Figure 20: Trends in antibody therapy for rejection episodes fol-
lowing lung transplantation, 1992–2001.
Heart-Lung Transplantation
Trends in induction therapy in heart-lung
transplantation
The trends for the use of induction therapy in heart-lung
transplantation have been somewhat erratic. The reason
for this is that the overall number of en-bloc heart-lung
transplants has decreased from a peak of 71 transplants
in 1994 to as low as 27 in 2001 (32 in 2002). Thus, infer-
ence of trends in such small numbers is difficult. In gen-
eral, over the last decade there has been a gradual increase
in the percentage of patients receiving induction therapy,
from 12% in 1993 to 59% in 2002. The changes in prac-
tice, however, appear to be somewhat random. The use
of equine antithymocyte globulin peaked in 1995 at 44%
and declined to 16% in 2002. The use of muromonab-CD3
remained relatively stable (6% in 2002). The use of rabbit
antithymocyte globulin increased from 0% 4 years ago to a
peak in 2001 at 12% (3% in 2002). The use of anti-IL-2 re-
ceptor antibodies (daclizumab and basiliximab) increased
from 0% 5 years ago to 34% in 2002. The use of either
equine antithymocyte globulin or an anti-IL-2 receptor anti-
body appears to be the dominant strategy for induction in
heart-lung transplantation.
Trends in maintenance immunosuppression therapy
prior to discharge in heart-lung transplantation
As in heart transplantation, from 1993 to 2002 there have
been no major changes in the general scheme of immuno-
suppression therapy prior to discharge for heart-lung trans-
plant recipients. Shifts within the certain specific classes of
immunosuppressants have not been as dramatic as seen
with other organ types.
Calcineurin inhibitors. Calcineurin inhibitor use at the time
of discharge remains essentially 100%. Cyclosporine use
has fallen from a high of 93% in 1994 to 62% in
2002. Of those who received cyclosporine, most received
Neoral®. A small proportion received either Sandimmune®
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or Gengraf®. In contrast, the use of tacrolimus increased
substantially. Tacrolimus is now used in 43% of heart-lung
transplant recipients at the time of discharge.
Antimetabolites and rapamycin. The use of antimetabolites
(azathioprine and mycophenolate mofetil) at the time of
discharge has remained fairly constant over the past 10
years, ranging from 94% in 1993 to 95% in 2002. Although
the use of azathioprine has declined and the use of my-
cophenolate mofetil has proportionally risen, this has not
occurred to the same extent as is seen in heart transplan-
tation. In 2002, azathioprine was used in 52% of heart-lung
transplant recipients at the time of discharge and mycophe-
nolate mofetil was used in 48%. The use of other agents
such as rapamycin has not occurred in heart-lung transplant
patients at the time of discharge.
Corticosteroids. The use of corticosteroids has fluctuated
a little in the past decade (a low of 88% in 1996, a high of
100% in 1999–2002).
Trends in maintenance immunosuppression therapy
for the first year in heart-lung transplantation
Calcineurin inhibitors. Cyclosporine or tacrolimus remain
the cornerstones of maintenance immunosuppression in
heart-lung transplant recipients. Over the past 10 years,
there has been a trend towards less use of cyclosporine
and more use of tacrolimus. Cyclosporine use has de-
creased from 81% in 1992 to 50% in 2001, with Neoral®
being the most frequent formulation. During the same time
interval, the use of tacrolimus has increased greatly, from
19% to 75%.
Antimetabolites and rapamycin. Although antimetabolites
are still used frequently within the first year after heart-lung
transplantation, there has been a shift in practice over the
last decade. The use of azathioprine declined from 97% in
1992 to 50% in 2001. Concurrently, the use of mycopheno-
late mofetil rose to 60%. The use of rapamycin increased
to 10% in 2000, however no first-year heart-lung patients
received rapamycin in 2001.
Corticosteroids. The vast majority of heart-lung transplant
recipients were treated with corticosteroids as part of
maintenance therapy during the first year after transplan-
tation. In 2001, 95% of heart-lung transplant recipients re-
ceived either prednisone or methylprednisolone.
In 2001, the most common maintenance therapy combina-
tion for the small numbers of heart-lung transplant recipi-
ents within the first year after transplantation consisted of
corticosteroids, tacrolimus, and mycophenolate mofetil.
Trends in antirejection treatment in heart-lung
transplantation
For first-year transplant recipients who require therapy for
rejection, the use of corticosteroids has remained between
80% and 100% in the small number of patients who have
received heart-lung transplants. During the last 10 years,
the use of therapy with antibodies varied from 10% to
20%. When antibody therapy was used, muromonab-CD3,
equine antithymocyte globulin, rabbit antithymocyte glob-
ulin and anti-IL-2 receptor antibodies were all used with
no clear trends, given the small numbers of transplanted
patients.
Comparison of Organs
Trends in induction therapy
The proportion of patients receiving induction therapy var-
ied widely among organs (Figure 21). The highest use of in-
duction therapy was reported for SPK and PAK transplants.
Its use was reported in over 70% of the recipients in 2002;
this was followed by PTA (67%), kidney (65%), intestine
(57%), and thoracic (over 40%). Induction was not very
common in liver transplants and was reported in only 18%
of recipients in 2002.
In the earlier years, muromonab-CD3 was the predomi-
nant induction agent used in most organs, except in tho-
racic transplantation, where the use of equine antithymo-
cyte globulin was as common. A switch from equine an-
tithymocyte globulin or muromonab-CD3 as the primary
induction agent to IL-2 receptor antagonists (basiliximab
and daclizumab) occurred in either 1998 or 1999 for kidney,
kidney-pancreas, pancreas, liver, and intestine, followed by
a switch from IL-2 receptor antagonists to rabbit antithy-
mocyte globulin in 2000 or 2001. In 2002, rabbit antithy-
mocyte globulin was used more often than IL-2 receptor
antagonists for pancreas, kidney-pancreas, and intestine,
whereas IL-2 receptor antagonists were used more com-
monly than rabbit antithymocyte globulin for liver and kid-
ney transplants.
Both muromonab-CD3 and equine antithymocyte globulin
were reported as common induction agents for thoracic
organs in the earlier years and were replaced by IL-2 re-

















Source: 2003 OPTN/SRTR Annual Report, Table 5.6–13.6.
Figure 21: Comparative use of immunosuppression for induction
prior to discharge, all organs, 2002.
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and heart-lung. While a switch to rabbit antithymocyte glob-
ulin occurred in 2002 for heart, IL-2 receptor antagonists
remained the more common induction agent for lung and
heart-lung in 2002.
Trends in maintenance immunosuppression therapy
prior to discharge
Immunosuppressive regimens used for maintenance ther-
apy at discharge varied by organ (Figures 22 and 23). The
use of corticosteroids as discharge maintenance immuno-
suppression was reported in the majority of transplant re-
cipients. Corticosteroids were used in over 87% of recipi-
ents of kidney, SPK, PAK, and thoracic transplants, and in
over 70% of recipients of PTA. The use of corticosteroids
in intestine transplants was reported in over 80% of recip-
ients until 2002, where the use was reported in only 64%
of recipients.
Cyclosporine was the most-used calcineurin inhibitor in
most organs until the introduction of tacrolimus around
1994. A switch from cyclosporine to tacrolimus occurred
in 1995 for pancreas, in 1996 for liver, in 1997 for SPK, and
in 2001 for kidney. Cyclosporine remained the calcineurin
inhibitor agent of choice for heart and heart-lung through
2002, whereas a switch to tacrolimus was noted for lung
in 2002. For intestine, tacrolimus has been the predom-
inant calcineurin inhibitor agent since 1994. In 2002, the
proportion of recipients reported with tacrolimus as dis-
charge maintenance immunosuppression was 63% for kid-
ney, 95% for PTA, 86% for PAK, 87% for SPK, 87% for liver,
96% for intestine, 39% for heart, 57% for lung, and 43%
for heart-lung.
Azathioprine was the favored antimetabolite agent for
most organs until the introduction of mycophenolate
mofetil in late 1995. A switch from azathioprine to my-
cophenolate mofetil occurred in 1996 for kidney, pancreas,
SPK, and intestine, in 1997 for liver, and in 1999 for heart.
Azathioprine remained the antimetabolite agent of choice
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Source: 2003 OPTN/SRTR Annual Report, Table 5.6–13.6.
Figure 22: Comparative calcineurin inhibitor use for immunosup-
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Source: 2003 OPTN/SRTR Annual Report, Table 5.6–13.6.
Figure 23: Comparative use of antimetabolites and rapamycin im-
munosuppression prior to discharge, all organs, 2002.
tion of recipients reported with mycophenolate mofetil as
discharge maintenance immunosuppression was 79% for
kidney, 64% for PTA, 74% for PAK, 79% for SPK, 48% for
liver, 11% for intestine, 75% for heart, 45% for lung, and
48% for heart-lung.
The use of rapamycin started to emerge in 2000 for all
organs except heart-lung. In 2002, the use of rapamycin
ranged from 15% to 20% in kidney, pancreas, SPK, and
intestine transplants. During the same year, rapamycin was
reported in 7% of liver, 10% of heart, and only 2% of lung
transplant recipients.
Trends in maintenance immunosuppression therapy
between discharge and 1 year post-transplant
The use of corticosteroids between discharge and 1 year
after transplant was reported in the majority of transplant
recipients. For transplants performed in 2001, the propor-
tion of recipients with corticosteroids between discharge
and 1 year ranged from 86% for intestine to 100% for lung.
Cyclosporine was the most reported maintenance cal-
cineurin inhibitor between discharge and 1 year post-
transplant in most organs until about 1994. A switch from
cyclosporine to tacrolimus occurred for transplants per-
formed in 1994 for PTA, in 1995 for liver, in 1996 for
PAK, in 1997 for SPK, in 2000 for lung, and in 2001 for
kidney and heart-lung. For heart, cyclosporine remained
the calcineurin inhibitor agent of choice, whereas for in-
testine, tacrolimus has been the predominant calcineurin
inhibitor agent since 1994. For transplants performed in
2001, the proportion of recipients reported with tacrolimus
as maintenance immunosuppression between discharge
and 1 year was 64% for kidney, 99% for PTA, 93% for
PAK, 89% for SPK and liver, 100% for intestine, 43% for
heart, 69% for lung, and 75% for heart-lung.
A switch from azathioprine to mycophenolate mofetil oc-
curred for transplants performed in 1995 for PTA, in 1996
for kidney, PAK, SPK, liver, and intestine, in 1997 for heart,
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in 2001 for lung, and in 2000 for heart-lung. Although a
switch from azathioprine to mycophenolate mofetil had
occurred for intestinal transplants performed since 1996,
azathioprine became the antimetabolite agent of choice
again for transplants done in 2001. For lung, azathioprine
remained the antimetabolite agent of choice, although it
was used at a comparable rate to mycophenolate mofetil
for transplants done in 2001 (50% vs. 52%). For transplants
performed in 2001, the proportion of recipients reported
with mycophenolate mofetil between discharge and 1 year
was 80% for kidney, 75% for PTA, 79% for PAK, 78% for
SPK, 50% for liver, 81% for heart, 52% for lung, 60% for
heart-lung, and only 3% for intestine.
For most organs, the use of rapamycin between discharge
and 1 year post-transplant started to emerge for transplants
done in 1999 or 2000. For transplants performed in 2001,
the use of rapamycin between discharge and 1 year ranged
from 0% for heart-lung to 29% for PAK transplants.
Trends in antirejection treatment between discharge
and 1 year post-transplant
Although the proportion of recipients reported with an-
tibody treatment for rejection may have fluctuated over
the years, overall there was a decreasing trend in its use
between transplant and 1 year post-transplant for most
organs. For transplants done in 1994, for example, 53%
of kidney, over 60% of SPK and pancreas, about 30% of
liver and intestine, and over 17% of thoracic transplants
were reported with nonsteroid antirejection therapy be-
tween discharge and 1 year post-transplant. In contrast,
in 2002, 37% of kidney, 62% of PTA, 63% of PAK, 30%
of SPK, 17% of liver, 16% of heart, 12% of lung, and 0%
of heart-lung transplants were reported with noncorticos-
teroid antirejection therapy between discharge and 1 year
post-transplant. Interestingly, the proportion of intestinal
transplants treated for rejection remained at 35%.
The use of corticosteroids for antirejection therapy was
more common than use of an antibody agent for most or-
gans. Corticosteroids were the most common treatment
for rejection between discharge and 1 year post-transplant
for transplants done in 2001 for at least 80% of kidney, PAK,
SPK, liver, and intestine recipients. Over 90% of PTA, heart,
lung, and heart-lung transplants in 2001 were reported to
have been performed with corticosteroids.
For most organs, muromonab-CD3 was the most com-
mon antibody therapy used to treat rejection between dis-
charge and 1 year post-transplant during the earlier years.
For transplants done in 2001, the proportion of recipients
reported with muromonab-CD3 was 11% for kidney, 29%
for PTA, 28% for PAK, 12% for SPK, 33% for intestine,
and less than 10% for liver, heart, and lung transplants.
ALG was also used in most organs except liver and in-
testine until about 1994, when it was replaced by equine
antithymocyte globulin. The use of equine antithymocyte
globulin as an antirejection agent was more common in
thoracic transplants during the more recent years and was
comparable with the use of muromonab-CD3.
The use of rabbit antithymocyte globulin as an antirejection
therapy started to be reported for transplants performed in
1999 for most organs. For transplants performed in 2001,
the proportion of recipients reported with rabbit antithy-
mocyte globulin rejection therapy between discharge and
1 year post-transplant was 18% for kidney, 17% for SPK,
38% for PTA, 35% for PAK, 5% for liver and heart, 8% for
intestine, and 6% for lung.
Summary
This review has documented marked changes in the
use of immunosuppressive agents in solid organ
transplantation over the past decade. Several consisten-
cies have emerged with respect to the use of maintenance
immunosuppression. There has been a transition within
the calcineurin inhibitor era from the dominant use of cy-
closporine to tacrolimus and the near ubiquitous use of
mycophenolate mofetil over azathioprine. Chronic use of
corticosteroids remains a mainstream practice despite in-
creased attention to successful steroid-sparing strategies.
Induction therapy is being incorporated into immunosup-
pression protocols with increasing frequency. The agents
employed are mostly IL-2 receptor antagonists, but clear
trends indicate that T-cell depletion is being used more of-
ten. The result of these changes in clinical practice seems
to indicate that the short-term outcomes have improved
based on the observation that rates of rejection within the
first year post-transplant have diminished (20). Future sur-
veys of trends in immunosuppression use are unlikely to
show a great deal of change over the next few years, but
subtle signs of immunosuppression minimization (dimin-
ished use of steroids) and new induction therapies (e.g.
Campath®) are likely to surface. Ultimately, one would like
to know how today’s choices of immunosuppression will
affect outcomes in the long term. Future reports will be
able to answer those questions.
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